Letter addresses treatment persistence and safety of first-line therapies for ulcerative proctitis, indicating ongoing discussions in inflammatory bowel diseases research.
Journal Article Response to Letter to the Editor Regarding "Real-World Comparison of Effectiveness, Treatment Persistence, and Safety of First-Line Advanced Therapies at One Year for Ulcerative Proctitis" Get access Rahul S Dalal, MD, MPH , Rahul S Dalal, MD, MPH Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States Corresponding author: Rahul S. Dalal, Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Harvard Medical School, 850 Boylston Street, Suite 201, Chestnut Hill, MA 02467, United States ([email protected]). https://orcid.org/0000-0003-4622-8441 Search for other works by this author on: Oxford Academic PubMed Google Scholar Jessica R Allegretti, MD, MPH Jessica R Allegretti, MD, MPH Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States https://orcid.org/0000-0003-3585-2425 Search for other works by this author on: Oxford Academic PubMed Google Scholar Inflammatory Bowel Diseases, izaf157, https://doi.org/10.1093/ibd/izaf157 Published: 21 August 2025
No takes yet. Share an insight, caveat, or question.
Dalal et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: